Covered recipient · General Payments record
ALLISON BRITT KIMMINS
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2020–2025
$2,443.02
- Reported across 122 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $334.08 | 17 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $128.16 | 7 |
| Janssen Biotech, Inc. | $44.14 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $38.60 | 2 |
| Incyte Corporation | $29.24 | 1 |
| Amgen Inc. | $24.67 | 1 |
| PFIZER INC. | $19.00 | 1 |
| LEO Pharma Inc. | $17.83 | 1 |
| Galderma Laboratories, L.P. | $17.62 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.82 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.17 | 01/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201562314 | CMS |
| ABBVIE INC. | $20.13 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201562316 | CMS |
| ABBVIE INC. | $15.93 | 08/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201562318 | CMS |
| ABBVIE INC. | $15.93 | 08/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201562320 | CMS |
| ABBVIE INC. | $29.44 | 09/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201562322 | CMS |
| ABBVIE INC. | $16.63 | 09/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201562324 | CMS |
| ABBVIE INC. | $15.93 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201562326 | CMS |
| Amgen Inc. | $24.67 | 01/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228343598 | CMS |
| Galderma Laboratories, L.P. | $17.62 | 06/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234622510 | CMS |
| Incyte Corporation | $29.24 | 06/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1226016902 | CMS |
| Janssen Biotech, Inc. | $20.87 | 05/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1175255209 | CMS |
| Janssen Biotech, Inc. | $23.27 | 10/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1175255421 | CMS |
| LEO Pharma Inc. | $17.83 | 02/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251994984 | CMS |
| Novartis Pharmaceuticals Corporation | $23.33 | 06/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200157934 | CMS |
| Novartis Pharmaceuticals Corporation | $15.27 | 10/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200157940 | CMS |
| PFIZER INC. | $19.00 | 08/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229774637 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.82 | 05/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1250966385 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2021, 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.